ABCL Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Earnings

AbCellera Biologics delivered a sharp earnings beat in Q4 2025, with revenue of $44.90 million coming in well above the $6.71 million consensus estimate, a 569.55% positive surprise, as the quarter's results were driven primarily by an upfront paymen… Read more AbCellera Biologics delivered a sharp earnings beat in Q4 2025, with revenue of $44.90 million coming in well above the $6.71 million consensus estimate, a 569.55% positive surprise, as the quarter's results were driven primarily by an upfront payment from a patent litigation settlement. That single item propelled quarterly revenue 789.1% higher year over year and lifted full-year 2025 revenue to $75.13 million, compared to $28.83 million in 2024. On the bottom line, AbCellera posted a loss of $0.03 per share, beating the $0.18 consensus estimate by 83.33%, as the settlement proceeds sharply narrowed the quarterly net loss to $8.90 million. The strong print coincided with the company's transition to a clinical-stage biotech, having advanced ABCL635 into Phase 2 and ABCL575 into Phase 1 trials during the year; both programs are expected to deliver topline readouts in the second half of 2026. With roughly $700 million in total available liquidity, including non-dilutive government funding, AbCellera says it is funded well beyond three years, supporting continued pipeline investment and at least three anticipated IND submissions in 2027. Shares rose nearly 19% following the results.